Eli Lilly and Shaquille O’Neal Raise Awareness of Treatable Sleep Apnea with Zepbound
INDIANAPOLIS, United States, June 10, 2026 Eli Lilly and Company has launched a nationwide awareness campaign featuring NBA legend...
GLP-1
Advertisement
Waters Launches New Platform for GLP-1 and LNP Analytics
MILFORD, Massachusetts, USA – June 8, 2026 Waters Corporation has introduced its BioResolve™ Peptide and GTxResolve™ Lipid Phenyl-Hexyl+ and...
Engitix and GSK Partner to Advance Liver Fibrosis Drug Discovery
London, UK – June 8, 2026 Engitix Ltd., a biotechnology company specializing in extracellular matrix (ECM)-driven drug discovery, has...
Lilly’s Foundayo Outperforms Rivals in Landmark Diabetes Trials
INDIANAPOLIS, USA – June 8, 2026 Eli Lilly and Company has reported compelling new Phase 3 clinical data showing...
Boehringer’s Survodutide Delivers Major Metabolic Benefits
INGELHEIM, Germany – June 7, 2026 Boehringer Ingelheim has reported positive Phase III results for its investigational glucagon/GLP-1 dual...
Advertisements
Zealand Pharma Highlights Positive Phase III Survodutide Results in Obesity
COPENHAGEN, Denmark, June 7, 2026 Zealand Pharma A/S announced that its partner Boehringer Ingelheim presented detailed results from the...
Roche Highlights Promising Obesity Pipeline Data Ahead of ADA 2026
Basel, Switzerland, June 1, 2026 Roche announced that new clinical data from its obesity portfolio will be presented at...
Genentech Advances Obesity Portfolio with New ADA 2026 Data
SOUTH SAN FRANCISCO, Calif., May 31, 2026 Genentech, a member of the Roche Group, announced that new clinical data...
Lilly Unveils Landmark Phase 3 Data for Foundayo and Retatrutide at ADA 2026
INDIANAPOLIS, May 28, 2026 Eli Lilly and Company has announced a major slate of scientific presentations for the American...
Novo Nordisk’s Wegovy 7.2 mg Wins CHMP Support
BAGSVÆRD, Denmark, May 22, 2026 Novo Nordisk announced that the European Medicines Agency’s Committee for Medicinal Products for Human...
Advertisement
